Navigation Links
Codexis, Raizen to Develop First Generation Ethanol
Date:9/27/2011

REDWOOD CITY, Calif. and SAO PAULO, Sept. 27, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) and Raizen Energia S.A. today announced the signing of a joint development agreement to develop an improved first generation ethanol process with enhanced performance economics. Raizen is Brazil's largest sugar and ethanol producer.  

Under the terms of the agreement, Raizen and Codexis will deploy the Codexis CodeEvolver™ directed evolution technology platform to improve Raizen's current process for producing ethanol made from sugar.  Raizen produced 600 million gallons of ethanol in 2010.  The agreement focuses on a range of targets, including improving performance of yeasts now used in ethanol production.  The parties anticipate pilot production at Raizen's Bonfim mill.

Codexis will retain commercialization rights and Raizen will receive preferential commercial terms.  Successful developments under the collaboration will be covered by subsequent agreements. The collaboration may also include development of other products from sugar such as biobased chemicals.

Brazil is the world's second largest producer and consumer of ethanol, with 2010 production of 7 billion gallons.  Brazil is currently importing ethanol as a result of rising demand and lower current-season yields.  

"This agreement is very timely, since sugarcane ethanol in Brazil clearly needs to continue improving productivity to achieve expected yields in the years to come. Raizen and Codexis strongly believe that investing in technology is a critical path to achieve this," said Vasco Diaz, Raizen Chief Executive Officer.

"We are delighted to announce our first agreement with Raizen. Working together, we expect to quickly improve the performance and cost structure of first generation ethanol, now in use throughout Brazil.  We look forward to a
'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Codexis, Inc. Announces Pricing of Initial Public Offering
3. Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Promising Cystic Fibrosis Compound on Track for Development
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
11. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... - Broadened Diagnostic Criteria and Growing ... despite Patent Expirations ... Therapeutics to 2020 - Broadened Diagnostic ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... April 15, 2011 HeartWare International, Inc. (NASDAQ: ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced the presentation of updated data ... study, ADVANCE, showing 180-day survival, using Kaplan-Meier analysis, ...
... Md., April 15, 2011 The U.S. Food and ... device to treat adults with glioblastoma multiforme (GBM) that ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the brain tissue. According to the National Cancer Institute, ...
Cached Medicine Technology:HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5FDA Approves New Medical Device for Form of Brain Cancer 2FDA Approves New Medical Device for Form of Brain Cancer 3
(Date:8/28/2014)... Career Step, an online provider of ... video designed to help students and career seekers explore ... field. The video details what medical coders and billers ... and the education requirements for entering this field. , ... overlooked when people are considering a career in healthcare,” ...
(Date:8/28/2014)... (PRWEB) August 29, 2014 VPS ... a physical server computer into many servers, each ... running on someone’s own dedicated computer. Top10BestSEOHosting.com has ... announces that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ), Bluehost and ... suppliers in 2014. , The IT manager of ...
(Date:8/28/2014)... AltMed , a fully ... to the development and production of medical cannabis, ... location in Sarasota County. , "Sarasota County ... commitment to attracting new industry and the job ... Wright, President and CEO of AltMed. "Their responsive ...
(Date:8/28/2014)... Fifty percent of adults who seek medical ... percent of Americans claim to have fatigue that is ... Fatigue is the most common yet overlooked cause of ... symptoms. Tasks that were once a breeze are now ... cause irritation, experiencing weight gain around the middle area ...
(Date:8/28/2014)... August 28, 2014 When David Gergen, ... long-time friend of Mark Brnovich, was asked to publicly ... nomination for the Attorney General seat in the State ... gathered the support of Cardinal Hall of Fame wide ... Derek Kennard and Mark Walczak. Green, Kennard and Walczak ...
Breaking Medicine News(10 mins):Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Top10BestSEOHosting.com Announces The Best Three VPS Hosting Suppliers 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Peoria AlignLife Clinics Focus on Community Education 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3
... , WARREN, Mich., Dec. ... treatments, radiological imaging...does this match the picture of a typical ... suffering with cancer, this description sadly fits best. The customary ... sit on Santa,s lap are removed, along with many other ...
... , WEST PALM BEACH, Fla., Dec. ... retained TransMedia Group to publicize the first major innovation ... Snap System, which is already saving hospitals millions in maintenance ... as Agency of Record to elevate Cubicle Curtain Factory,s profile ...
... ... Interdisciplinary Evidence-based Content throughout the Clinical Workflow , ... (PRWEB) December 7, 2009 -- Institutions currently using point-of-care ... benefit from a new agreement which gives healthcare providers integrated access to their evidence-based ...
... , PARSIPPANY, N.J., Dec. 7 Today the Centers for Disease ... Week. While the week was designed to highlight the importance of ... additional steps to keep you and your family healthy during the ... "It,s easy to get overwhelmed by all the information circulating around ...
... , OAK BROOK, Ill., Dec. 7 ... medical center (AMC) members for their achievements in UHC,s ... organizations are noted for modeling best practices in supply ... ) , The winners were determined using 2008 data ...
... researchers say , SUNDAY, Dec. 6 (HealthDay News) -- ... to other parts of the body is controlled by a ... target for new drugs to prevent metastatic breast cancer, British ... growth factor beta) regulates normal cell growth and movement. In ...
Cached Medicine News:Health News:Help Young Cancer Patients Enjoy Christmas This Season 2Health News:Cubicle Curtain Factory Retains TransMedia Group to Promote First Privacy Curtain to Reduce Hospital Maintenance Cost 2Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 2Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 3Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Breast Cancer's Spread Now Better Understood 2
... Our Buffered Wright-Giemsa Stain is ... contains the fixative, buffer, and ... staining of blood smears. It ... bottle for ease of use ...
... Giemsa stain is an excellent classical ... blood smears and bone marrow. Erythrocytes ... exhibiting a very light, pale pink. ... cytoplasm stains the classical "ground glass" ...
Albumin (BCP). Storage temp: 15 - 30 C. Linearity: 0.5 - 8.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 250 number of tests....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
Medicine Products: